Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab versus mepolizumab for relapsing or refractory EGPA
2019-001832-77Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic granulomatosis with polyangiitis (EGPA) comparing Benralizumab arm with Mepolizumab arm (2 arms). Primary endpoint: Remission at both Weeks 36 and 48. Started Aug 2019; status: active.
02
Drugs
benralizumabmepolizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on 2019-001832-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001832-77.